27626099|t|Peptide -Mediated Interference of PB2 - eIF4G1 Interaction Inhibits Influenza A Viruses ' Replication in Vitro and in Vivo
27626099|a|Influenza viruses are obligate parasites that hijack the host cellular system. Previous results have shown that the influenza virus PB2 subunit confers a dependence of host eukaryotic translation initiation factor 4-γ 1 (eIF4G1) for viral mRNA translation. Here, we demonstrated that peptide -mediated interference of the PB2 - eIF4G1 interaction inhibited virus replication in vitro and in vivo. Remarkably, intranasal administration of the peptide provided 100% protection against lethal challenges of influenza A viruses in BALB/c mice, including H1N1, H5N1, and H7N9 influenza virus subtypes. Mapping of the PB2 protein indicated that the eIF4G1 binding sites resided within the PB2 cap - binding domain. Virtual docking analysis suggested that the inhibitory peptide associated with the conserved amino acid residues that were essential to PB2 cap-binding activity. Overall, our results identified the PB2 - eIF4G1 interactive site as a druggable target for influenza therapeutics.
27626099	0	7	Peptide	T116	C0030956
27626099	18	30	Interference	T070	C0042730
27626099	34	37	PB2	T116,T123	C0753209
27626099	40	46	eIF4G1	T116,T123	C1505487
27626099	47	58	Interaction	T044	C0872079
27626099	59	67	Inhibits	T052	C3463820
27626099	68	87	Influenza A Viruses	T005	C0029347
27626099	90	101	Replication	T043	C0042774
27626099	102	110	in Vitro	T062	C0681828
27626099	115	122	in Vivo	T062	C0681829
27626099	123	140	Influenza viruses	T005	C0029341
27626099	145	163	obligate parasites	T204	C0562628
27626099	169	200	hijack the host cellular system	T043	C1154502
27626099	239	258	influenza virus PB2	T116,T123	C1611366
27626099	291	342	host eukaryotic translation initiation factor 4-γ 1	T116,T123	C1505487
27626099	344	350	eIF4G1	T116,T123	C1505487
27626099	356	378	viral mRNA translation	T046	C1154505
27626099	407	414	peptide	T116	C0030956
27626099	425	437	interference	T070	C0042730
27626099	445	448	PB2	T116,T123	C0753209
27626099	451	457	eIF4G1	T116,T123	C1505487
27626099	458	469	interaction	T044	C0872079
27626099	470	479	inhibited	T052	C3463820
27626099	480	497	virus replication	T043	C0042774
27626099	498	506	in vitro	T062	C0681828
27626099	511	518	in vivo	T062	C0681829
27626099	532	557	intranasal administration	T061	C0001560
27626099	565	572	peptide	T116	C0030956
27626099	587	597	protection	T033	C1545588
27626099	606	612	lethal	T033	C3151529
27626099	613	623	challenges	T058	C0805586
27626099	627	646	influenza A viruses	T005	C0029347
27626099	650	661	BALB/c mice	T015	C0025919
27626099	673	677	H1N1	T005	C1615607
27626099	679	683	H5N1	T005	C1613950
27626099	689	718	H7N9 influenza virus subtypes	T005	C3658219
27626099	720	727	Mapping	T063	C0949728
27626099	735	746	PB2 protein	T116,T123	C0753209
27626099	766	772	eIF4G1	T116,T123	C1505487
27626099	773	786	binding sites	T192	C0005456
27626099	806	813	PB2 cap	T116,T123	C0753209
27626099	816	830	binding domain	T044	C1149343
27626099	832	856	Virtual docking analysis	T170	C3494274
27626099	876	886	inhibitory	T052	C3463820
27626099	887	894	peptide	T116	C0030956
27626099	895	910	associated with	T080	C0332281
27626099	925	944	amino acid residues	T116,T121,T123	C0002520
27626099	968	971	PB2	T116,T123	C0753209
27626099	972	992	cap-binding activity	T059	C0201711
27626099	1030	1033	PB2	T116,T123	C0753209
27626099	1036	1042	eIF4G1	T116,T123	C1505487
27626099	1043	1059	interactive site	T192	C0005456
27626099	1065	1074	druggable	T121	C1254351
27626099	1086	1095	influenza	T047	C0021400
27626099	1096	1108	therapeutics	T061	C0087111